CLINICAL AND PARA-CLINICAL FEATURES OF MANTLE CELL LYMPHOMA AT K HOSPITAL

Huyền Nga Đỗ, Thị Kim Anh Đỗ, Thanh Tùng Nguyễn

Main Article Content

Abstract

Objective: Describe the clinical and paraclinical characteristics of Mantle cell lymphoma. Subjects and methods: A cross-sectional descriptive prospective study was conducted on 73 patients with mantle cell lymphoma treated with RDHAP/RCHOP or RB/RBAC regimens at the Hematologic Oncology Department, K Hospital from May 2019 to May 2024. Results: The average age was 60; The male/female ratio was ~2.17; PS 0 accounted for 87.7%. Syndrome B occurred in 27.4% of patients; Patients admitted to the hospital due to lymphadenopathy accounted for 64.4%; The median lesion size was 4.0 cm. Bulky lesions accounted for 17.8%; The most common lymph node lesions were abdominal lymph nodes (84.9%) and head and neck lymph nodes (72.6%); There were 48 patients with extranodal lesions accounting for 65.8%, of which the highest rate of lesions in the colon was 27.4% and the stomach was 24.7%; the rate of low or intermediate MIPI risk group was 32%; high risk was 36%; patients were mainly in stage 3 or 4 accounting for 86%. Conclusion: The characteristic clinical features of mantle cell lymphoma support doctors in the process of early diagnosis and timely and appropriate treatment selection for these patients.

Article Details

References

Arnold S Freedman. Mantle cell lymphoma: Epidemiology, pathobiology, clinical manifestations, diagnosis, and prognosis. Uptodate. 2024:1-25.
2. Carlo Visco, Silvia Finotto, Renato Zambello et al. Combination of Rituximab, Bendamustine, and Cytarabine for Patients With Mantle-Cell Non-Hodgkin Lymphoma Ineligible for Intensive Regimens or Autologous Transplantation. Journal of clinical oncology. 2013:1442-1449.
3. Carlo Visco. Long-term follow-up of rituximab plus bendamustine and cytarabine in older patients with newly diagnosed MCL. Blood Adv. 2023:3916–3924.
4. LaCasce AS. Comparative outcome of initial therapy for younger patients with mantle cell lymphoma: an analysis from the NCCN NHL Database. Blood. 2012:2093.
5. Linton K., Dreyling M. EHA Endorsement of ESMO Clinical Practice Guidelines for Newly Diagnosed and Relapsed Mantle Cell Lymphoma. Hemasphere. 2020:464.
6. Olivier Hermine, Eva Hoster, Jan Walewski et al. Addition of high-dose cytarabine to immunochemotherapy before autologous stem-cell transplantation in patients aged 65 years or younger with mantle cell lymphoma (MCL Younger): a randomised, open-label, phase 3 trial of the European Mantle Cell Lymphoma Network. Lancet. 2016:565-575.
7. Schulz H. Immunochemotherapy with rituximab and overall survival in patients with indolent or mantle cell lymphoma: a systematic review and meta-analysis. J Natl Cancer Inst. 2007:706.